NCM
Nantahala Capital Management Portfolio holdings
AUM
$1.68B
1-Year Est. Return
115.06%
This Fund
S&P 500
1 Year Est. Return
+115.06%
AUM
$1.68B
AUM Growth
+$58.5M
(+3.6%)
Holding
160
Top Buys
| 1 | +$49.8M | |
| 2 | +$28.8M | |
| 3 | +$27.8M | |
| 4 |
Soleno Therapeutics
SLNO
|
+$24.7M |
| 5 |
Peloton Interactive
PTON
|
+$15.7M |
Top Sells
| 1 | +$59.5M | |
| 2 | +$44.1M | |
| 3 | +$35.3M | |
| 4 |
Amneal Pharmaceuticals
AMRX
|
+$20.3M |
| 5 |
IMAX
IMAX
|
+$18.1M |
Sector Composition
| 1 | Healthcare | 62.18% |
| 2 | Consumer Discretionary | 15.78% |
| 3 | Financials | 6.34% |
| 4 | Communication Services | 5.5% |
| 5 | Industrials | 2.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Regeneron Pharmaceuticals
REGN
$81.6B
| – | – |
0
|
|
||
|
SCPH
152
DELISTED
scPharmaceuticals
SCPH
| – | – |
-861,277
|
|
||
153
Teva Pharmaceuticals
TEVA
$36.7B
| – | – |
0
|
|
||
154
VistaGen Therapeutics
VTGN
$24.2M
| – | – |
-1,978,492
|
|
||
155
Viatris
VTRS
$16.2B
| – | – |
0
|
|
||
156
State Street SPDR S&P Biotech ETF
XBI
$8.09B
| – | – |
0
|
|
||
|
PVLA
157
Palvella Therapeutics
PVLA
$1.99B
| – | – |
-250,062
|
|
||
|
MAZE
158
Maze Therapeutics
MAZE
$2.46B
| – | – |
-93,351
|
|
||
|
CHYM
159
Chime Financial
CHYM
$8.48B
| – | – |
0
|
|